Arabic Arabic English English French French German German

Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Potential Registration Trial of Vidutolimod (CMP-001) in Patients with Anti-PD-1 Refractory Advanced Melanoma

Checkmate Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, announced that patient dosing was initiated in a Phase 2 trial intended to assess the efficacy and safety of vidutolimod in combination with nivolumab for the treatment of patients with anti-PD-1 refractory advanced melanoma. Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Documentary Exposes the Alarming Truth — TV Puts Us In Hypnotic State and Suppresses Critical Thinking

Next Post

Standard Bariatrics® Titan SGS Stapling Technology for Sleeve Gastrectomy Receives FDA Clearance

Related Posts